Ownership and insider activity for Surrozen, Inc. (SRZN): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.
Price
| Price | $16.93 |
| Market Cap | $127M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-07-22 | TCG Crossover GP II, LLC | S-Sale | 162,500 | $3.5M |
| 2026-07-22 | TCG Crossover GP II, LLC | S-Sale | 162,500 | $3.5M |
| 2026-06-15 | Maleki Andrew Pedrum | A-Award | 607 | $12K |
| 2026-06-15 | Li Yang | A-Award | 1,666 | $14K |
| 2026-06-15 | Williams Charles O | A-Award | 1,666 | $14K |
| 2026-06-15 | Parker Craig C | A-Award | 1,622 | $13K |
| 2026-05-13 | Kutzkey Tim | A-Award | 5,550 | $167K |
| 2026-05-13 | Rothenberg Mace | A-Award | 5,550 | $167K |
| 2026-05-13 | WOODHOUSE DAVID J | A-Award | 5,550 | $167K |
| 2026-05-13 | Haak-Frendscho Mary | A-Award | 5,550 | $167K |
Balance Sheet (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $29.1M | $35.0M | $33.1M | $24.7M | $36.0M | $34.6M | $89.2M |
| Short-term Investments | 0 | $14.2M | $68.8M | $51.1M | 0 | 0 | 0 |
| Receivables | 0 | 0 | 0 | $2.0M | $2.2M | $2.5M | $208000 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $29.4M | $50.2M | $105.2M | $81.3M | $41.1M | $38.9M | $91.6M |
| Property, Plant & Equipment | $12.6M | $11.4M | $9.4M | $6.9M | $3.9M | $8.4M | $6.4M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $42.5M | $62.1M | $137.2M | $89.4M | $46.1M | $48.5M | $98.7M |
| Accounts Payable | $972000 | $1.8M | $2.7M | $658000 | $525000 | $306000 | $728000 |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $3.9M | $7.3M | $13.6M | $9.7M | $7.1M | $7.3M | $9.9M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $13.1M | $14.8M | $27.5M | $13.4M | $8.1M | $69.8M | $286.5M |
| Retained Earnings | -$55.3M | -$88.0M | -$142.6M | -$178.7M | -$221.7M | -$285.3M | -$527.3M |
| Total Equity | $29.4M | $47.3M | $109.7M | $76.0M | $37.9M | -$21.4M | -$187.8M |
| Total Debt | $10.7M | $9.6M | $7.8M | $5.6M | $3.4M | $8.5M | $6.6M |
| Net Debt | -$18.4M | -$39.6M | -$94.1M | -$70.2M | -$32.7M | -$26.1M | -$82.6M |
| Working Capital | $25.5M | $42.9M | $91.6M | $71.6M | $34.0M | $31.6M | $81.6M |
Financial Health
| Debt / Equity | -0.03 |
| Current Ratio | 12.14 |
Profitability
| Return on Equity | 187.62% |
| Return on Invested Capital | -40.84% |
| Return on Assets | -287.29% |
| Gross Margin | 99.44% |
| Operating Margin | -385.28% |
| Net Margin | -2885.33% |
Related companies: AGEN · ATOS · CGTX · GLSI · IMMX · IRD · SEER
Explore sector: Healthcare · Biotechnology
More sections of SRZN: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks